Total sample, % (n/total n) | Without hypoglycaemic event, % (n/total n) | At least one hypoglycaemic event, % (n/total n) | OR (95% IC) | P values | |
At least one antidiabetic drug | 45 (167/373) | 37 (114/309) | 83 (53/64) | 8.2 (4 to 18.1) | <0.001 |
Insulin | 26 (96/373) | 16 (50/309) | 72 (46/64) | 13.1 (6.8 to26.1) | <0.001 |
Fast acting* | 13 (49/373) | 7 (23/309) | 41 (26/64) | 8.4 (4.2 to17.2) | <0.001 |
Medium acting† | 23 (87/373) | 15 (45/309) | 66 (42/64) | 11.1 (5.9 to 21.5) | <0.001 |
Long acting‡ | 1 (2/373) | 0 (1/309) | 2 (1/64) | 4.9 (0.1 to 383.7) | 0.3 |
Mixed insulin | 1 (3/373) | 1 (2/309) | 2 (1/64) | 2.4 (0 to 47.3) | 0.4 |
Insulin as monotherapy | 17 (65/373) | 10 (31/309) | 53 (34/64) | 10.1 (5.2 to 19.7) | <0.001 |
Insulin secretagogues | 8 (28/373) | 6 (17/309) | 17 (11/64) | 3.5 (1.4 to 8.6) | 0.003 |
Sulfonylureas | 6 (24/373) | 5 (16/309) | 13 (8/64) | 2.6 (0.9 to 6.8) | 0.05 |
Glinides | 1 (4/373) | 0 (1/309) | 5 (3/64) | 15 (1.2 to 793) | 0.02 |
Insulin secretagogues as monotherapy | 2 (8/373) | 2 (5/309) | 5 (3/64) | 3 (0.5 to 15.8) | 0.1 |
Other antidiabetics | 25 (92/373) | 25 (78/309) | 22 (14/64) | 0.8 (0.4 to 1.6) | 0.6 |
Metformin | 24 (88/373) | 24 (75/309) | 20 (13/64) | 0.8 (0.4 to 1.6) | 0.6 |
Dipeptidyl peptidase-4 inhibitors | 6 (22/373) | 6 (19/309) | 5 (3/64) | 0.8 (0.1 to 2.7) | 1 |
Glucagon-like peptide-1 receptor agonists | 1 (5/373) | 1 (3/309) | 3 (2/64) | 3.3 (0.3 to 29.2) | 0.2 |
Thiazolidinediones | 1 (2/373) | 1 (2/309) | 0 (0/64) | 0 (0 to 25.8) | 1 |
Other antidiabetics as monotherapy | 14 (51/373) | 17 (51/309) | 0 (0/64) | 0 (0 to 0.3) | <0.001 |
Combination | |||||
Insulin and insulin secretagogues | 1 (2/373) | 0 (0/309) | 3 (2/64) | Not calculable | 0.03 |
Insulin and other antidiabetics | 6 (23/373) | 5 (15/309) | 13 (8/64) | 2.8 (1 to 7.4) | 0.04 |
Insulin secretagogues and other antidiabetics | 3 (12/373) | 3 (8/309) | 6 (4/64) | 2.5 (0.5 to 9.7) | 0.1 |
Insulin, insulin secretagogues and other antidiabetics | 2 (6/373) | 1 (4/309) | 3 (2/64) | 2.5 (0.2 to 17.5) | 0.3 |
*Insulin lispro, insulin aspart, insulin glulisine, human insulin.
†Insulin protamin.
‡Insulin glargine, insulin detemir, insulin degludec.